- Home
- SNES vs QNRX Comparison
SNES vs QNRX Comparison
Compare SNES & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- QNRX
- Stock Information
- Founded
- SNES 2004
- QNRX 2018
- Country
- SNES United States
- QNRX United States
- Employees
- SNES N/A
- QNRX N/A
- Industry
- SNES Agricultural Chemicals
- QNRX Medical/Dental Instruments
- Sector
- SNES Industrials
- QNRX Health Care
- Exchange
- SNES Nasdaq
- QNRX Nasdaq
- Market Cap
- SNES 2.9M
- QNRX 3.3M
- IPO Year
- SNES 2016
- QNRX N/A
- Fundamental
- Price
- SNES $2.71
- QNRX $6.19
- Analyst Decision
- SNES Strong Buy
- QNRX
- Analyst Count
- SNES 1
- QNRX 0
- Target Price
- SNES $10.00
- QNRX N/A
- AVG Volume (30 Days)
- SNES 42.1K
- QNRX 40.5K
- Earning Date
- SNES 05-08-2025
- QNRX 05-13-2025
- Dividend Yield
- SNES N/A
- QNRX N/A
- EPS Growth
- SNES N/A
- QNRX N/A
- EPS
- SNES N/A
- QNRX N/A
- Revenue
- SNES $1,927,000.00
- QNRX N/A
- Revenue This Year
- SNES $130.53
- QNRX N/A
- Revenue Next Year
- SNES $80.00
- QNRX N/A
- P/E Ratio
- SNES N/A
- QNRX N/A
- Revenue Growth
- SNES 40.15
- QNRX N/A
- 52 Week Low
- SNES $1.30
- QNRX $5.01
- 52 Week High
- SNES $9.80
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- SNES 69.22
- QNRX 41.59
- Support Level
- SNES $2.27
- QNRX $6.05
- Resistance Level
- SNES $2.77
- QNRX $6.52
- Average True Range (ATR)
- SNES 0.22
- QNRX 0.68
- MACD
- SNES 0.08
- QNRX 0.14
- Stochastic Oscillator
- SNES 84.30
- QNRX 32.23
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.